Screening instrument for early detection of neurodegenerative disease progression

The time of diagnosis has a decisive influence on the treatment and spread of diseases.

Neurodegenerative diseases (e.g. Parkinson’s disease or Alzheimer’s disease) occur when brain cells lose their function over time and eventually die. This topic is becoming increasingly popular, especially in today’s society with regard to demographic change.

According to the current state of the art, diseases such as Parkinson’s and Alzheimer’s are only recognized when serious symptoms appear and a large number of brain cells are already affected.

There is currently a lack of screening methods to detect these diseases at a very early stage.

The company saniva diagnostics GmbH offers a solution to this problem. We have developed a medical device that is suitable as a comprehensive screening procedure.

The screening instrument, called NeuroMex, is based on the recording of motor responsiveness and has the potential to identify neurodegenerative diseases at a very early stage.

saniva diagnostics GmbH was founded as a spin-off of Jena University Hospital and is the patent holder.

Neuromex diagnostic

Our research and development project is subsidised by the ERDF (European Regional Development Fund) with funds from the European Union. FTI for single-company research and development projects.
Funding body: Thüringer Aufbaubank

Project number: 2019 FE 0151

Förderträger: Thüringer Aufbaubank

Vorhabennummer: 2019 FE 0151